You are here: Industry Insights > AML

News List

VENCLEXTA Receives FDA Approval for AML americanpharmaceuticalreview
October 22, 2020
AbbVie announced the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia ..
AbbVie’s Venclexta granted full US approval in AML pharmatimes
October 22, 2020
The US Food and Drug Administration (FDA) has fully approved AbbVie’s Venclexta in acute myeloid leukaemia (AML).
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia expresspharma
October 19, 2020
Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment ...
Accenture reveals data science project for paediatric leukaemia pharmatimes
September 30, 2020
Accenture Applied Intelligence announced a new data and analytics approach to manage and derive insights from paediatric acute myeloid leukaemia (AML) genomic data, with the potential to improve precision medicine.
Leukemia & Lymphoma Society Launches Trial for Blood Cancer Patients with COVID-19 americanpharmaceuticalreview
September 15, 2020
The Leukemia & Lymphoma Society (LLS) is launching the first clinical trial for blood cancer patients at risk of death if infected with the COVID-19 virus.
Kite, HiFiBiO Therapeutics partner to discover novel targets and antibodies against AML pharmaceutical-business-review
September 08, 2020
Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).
US FDA approves Onureg (azacitidine tablets) to treat acute myeloid leukaemia expresspharma
September 03, 2020
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukaemia (AML) ...
NICE publishes guidance on Astellas' Xospata pharmatimes
August 18, 2020
The National Institute for Health and Care Excellence has now published final guidance backing NHS use of Astellas' Xospata as monotherapy for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).
NICE backing for Astella's Xospata pharmatimes
July 20, 2020
NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).
Pfizer gets EC approval for Daurismo to treat newly diagnosed acute myeloid leukaemia pharmaceutical-business-review
July 02, 2020
Pfizer has secured approval from the European Commission (EC) for its Daurismo (glasdegib) to treat certain adult patients with newly diagnosed acute myeloid leukaemia (AML).

Previous page 1 2 3 4 5 6 7 8 9 10 Next page